155 Ces Urol 2024; 28(3): 141–157 PŘEHLEDOVÉ ČLÁNKY 26. Ferraro PM, Bargagli M. Dietetic and lifestyle recommendations for stone formers. Arch Esp Urol. 2021; 74(1): 112–22. 27. Yachantha C, Hossain RZ, Yamakawa K, et al. Effect of potassium depletion on urinary stone risk factors in Wistar rats. Urol Res [Internet]. 2009; 37(6): 311–6. Available from: http://dx.doi.org/10.1007/ s00240-009-0220-6. 28. Witting C, Langman CB, Assimos D, et al. Pathophysiology and treatment of Enteric hyperoxaluria. Clin J Am Soc Nephrol [Internet]. 2021; 16(3): 487–95. Available from: http://dx.doi.org/10.2215/cjn.08000520. 29. Lorenz EC, Lieske JC, Seide BM, et al. Sustained pyridoxine response in primary hyperoxaluria type 1 recipients of kidney alone transplant. Am J Transplant [Internet]. 2014; 14(6): 1433–8. Available from: http:// dx.doi.org/10.1111/ajt.12706. 30. Michael M, Groothoff JW, Shasha-Lavsky H, et al. Lumasiran for advanced primary hyperoxaluria type 1: Phase 3 ILLUMINATE-C trial. Am J Kidney Dis [Internet]. 2023; 81(2): 145-155.e1. Available from: http:// dx.doi.org/10.1053/j.ajkd.2022. 05. 012. 31. Perazella MA, Herlitz LC. The crystalline nephropathies. Kidney Int Rep [Internet]. 2021; 6(12): 2942–57. Available from: http://dx.doi.org/10.1016/j.ekir.2021. 09. 003. 32. Haque SK, Ariceta G, Batlle D. Proximal renal tubular acidosis: a not so rare disorder of multiple etio‑ logies. Nephrol Dial Transplant [Internet]. 2012; 27(12): 4273–87. Available from: http://dx.doi.org/10.1093/ ndt/gfs493. 33. Emmett MA. Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis. [Internet]. Uptodate.com. [cited 2024 Aug 8]. Available from: https://www.uptodate.com/contents/etiolo‑ gy-and-diagnosis-of-distal-type-1-and-proximal-type-2-renal-tubular-acidosis. 34. Mollerup CL. Risk of renal stone events in primary hyperparathyroidism before and after parathyroid surgery: controlled retrospective follow up study. BMJ [Internet]. 2002; 325(7368): 807–807. Available from: http://dx.doi.org/10.1136/bmj.325.7368.807. 35. Finkielstein VA. Strategies for preventing calcium oxalate stones. CMAJ [Internet]. 2006; 174(10): 1407–9. Available from: http://dx.doi.org/10.1503/cmaj.051517. 36. Massey LK, Roman-Smith H, Sutton RAL. Effect of dietary oxalate and calcium on urinary oxalate and risk of formation of calcium oxalate kidney stones. J Am Diet Assoc [Internet]. 1993; 93(8): 901–6. Available from: http://dx.doi.org/10.1016/0002-8223(93)91530-4. 37. Eisner BH, Porten SP, Bechis SK, Stoller ML. Diabetic kidney stone formers excrete more oxalate and have lower urine pH than nondiabetic stone formers. J Urol [Internet]. 2010; 183(6): 2244–8. Available from: http://dx.doi.org/10.1016/j.juro.2010. 02. 007. 38. Moe OW, Pearle MS, Sakhaee K. Pharmacotherapy of urolithiasis: evidence from clinical trials. Kidney Int [Internet]. 2011; 79(4): 385–92. Available from: http://dx.doi.org/10.1038/ki.2010.389. 39. Mensenkamp AR, Hoenderop JGJ, Bindels RJM. Recent advances in renal tubular calcium reabsorpti‑ on. Curr Opin Nephrol Hypertens [Internet]. 2006; 15(5): 524–9. Available from: http://dx.doi.org/10.1097/01. mnh.0000242179.38739.fb. 40. Ruml LA, Pearle MS, Pak CYC. Medical therapy. Urol Clin North Am [Internet]. 1997; 24(1): 117–33. Avai‑ lable from: http://dx.doi.org/10.1016/s0094-0143(05)70358-x. 41. Ettinger B, Tang A, Citron JT, Livermore B, Williams T. Randomized trial of allopurinol in the preven‑ tion of calcium oxalate calculi. N Engl J Med [Internet]. 1986; 315(22): 1386–9. Available from: http://dx.doi. org/10.1056/nejm198611273152204. 42. Kok DJ. Metaphylaxis, diet and lifestyle in stone disease. Arab J Urol [Internet]. 2012; 10(3): 240–9. Avai‑ lable from: http://dx.doi.org/10.1016/j.aju.2012. 03. 003.
RkJQdWJsaXNoZXIy NDA4Mjc=